Targeting 10x lower production cost

Transforming biomanufacturing economics

Fit-for-purpose manufacturing systems that unlock commercial profitability for bio-made products.

Concept render of a mobile, modular bioprocess skid rolling out of a shipping container Concept render
The problem

The science is ready. The economics are not.

Synthetic biology can now make food proteins, fats and oils, fuels and countless other products. Yet after two decades of innovation, very few companies have crossed the Valley of Death.

$20Binvested in synthetic biology, with a net negative return
<6%of companies truly profitable after two decades of science innovation
$100–400Mand 24–36 months to go from pilot to industrial scale

Unblok Bio has a single mission: solve the bio-made cost problem.

Where the cost hides

Balance of plant, not the equipment, drives the capex

Piping, utilities, graded facilities, commissioning and IT/OT dominate what it costs to build a bio-plant, so cheaper vessels alone won't fix the economics.

Equipment
Balance of plant
20–30% of capex
70–80% of capex · piping & utilities, graded facility, commissioning, IT/OT
~20%

of capex is equipment in a $500M cell-culture product plant

2.5–6 : 1

balance-of-plant spend relative to equipment spend

Up to 80%

of spend goes to production readiness, not production itself

Our approach

Four first-principles innovations, one target: 10x lower cost

Concept render of a fleet of mobile process equipment
1

Peer-to-peer transactional architecture

Mobile equipment connects directly through proprietary aseptic connectors, replacing fixed piping networks.

Attacks balance of plant
Concept render of a crane placing a modular skid in a warehouse
2

Plug-n-play, software-defined process

Modular equipment in a warehouse-grade facility; the process is defined and changed in software.

Attacks time to capacity
Mock-up of the plant fleet operating system
3

AI-native autonomous operation

One operating system schedules, dispatches and moves a mobile equipment fleet.

Attacks labor and IT/OT
Multi-stage bioreactor mathematical model: stages 1 to N in series with a recirculating loop
4

Proprietary process intensification

Multi-stage continuous bioreactor for higher volumetric productivity.

Attacks productivity
1 · Architecture

From fixed infrastructure to peer-to-peer transactions

We solve the connectivity problem once, so customers don't have to solve it again on every new project.

Conventional stick-built bioprocess plant with fixed piping

Conventional: fixed, stick-built infrastructure

  • Utility distribution network
  • CIP/SIP circuits
  • Process piping network
  • Clean room / graded suite
  • Engineering, design & construction management
Concept render of Unblok mobile equipment with peer-to-peer connections

Unblok: stationary + mobile equipment, peer-to-peer

  • Basic power, water and steam mains
  • Project management
  • Enabled by proprietary aseptic connection technology
2 · Plug-n-play

Bench to industrial scale in months, not years

Modular equipment deployed in warehouse-grade facilities. New production capacity comes online in months, and the same equipment is reconfigured in software.

Mock-up of the Unblok Bio Biomanufacturing Operating System showing equipment bays and a mobile fleet
3 · AI-native operations

One AI-native OS replaces the legacy plant software stack

ERPMESLIMSQMSHistorian
  • One non-hierarchical, cloud-centric architecture
  • Orchestrates mobile production workflows end to end
  • Intelligent scheduling, dispatching and on-the-fly rescheduling
  • Autonomous moving and docking of the mobile equipment fleet
4 · Process intensification

A multi-stage bioreactor for continuous production

3–5x

volumetric productivity vs. fed-batch

  • One bioreactor integrating multiple connected stages
  • Continuous, intensified cell or microbial culture
  • Curb Warburg/Crabtree effects for ultra-high product yield
Multi-stage bioreactor mathematical model: stages 1 to N in series with a recirculating loop
Impact on cost

Spend shifts from production readiness to production

ConventionalUnblok BioCost impact
Stick-built installationPlug-n-play deployment3–4x faster launch
Fixed piping networkPeer-to-peer transactions70–90% saving on balance of plant
Dedicated auxiliary equipmentShared mobile equipment fleet~50% saving on equipment
Fed-batchIntensified continuous process3–5x volumetric productivity
Complex dependenciesAI-native operating system60–80% saving on labor

Product-agnostic: the same system works for most bio-made products.

Proof points

The core technical risks are already validated

The integrated platform is new, but its core principles have been proven in separate operational settings.

3 days

Plug-n-play deployment assembled, installed and wet-tested at a customer facility.

Aseptic

Closed-operation cell culture run successfully in a warehouse, setting a sterility-duration record for the customer.

5 patents

Full tech stack mapped, with 5 core provisional patents filed.

TEA

Techno-economic analysis confirms capex and opex savings.

Markets

Better economics grow the 2035 market from $90B to $500B

Current projection
Unblocked

Serviceable addressable market, 2035.

Markets we unblock

  • Dairy proteins (casein, lactoferrin, whey), HMOs
  • Egg, algae and myco-proteins
  • Cultivated meat and seafood
  • Cultivated collagen, fat and oil
  • Jet fuel, bioplastic monomers, textiles, specialty chemicals
  • Flavors, pigments, probiotics, sweeteners, nutraceuticals
  • Plant cell culture products
  • Biostimulants, biopesticides, bioherbicides, biofertilizers
~150M haof land freed, about France, Spain and Germany combined
~1.1 Gt/yrCO₂e avoided, about Japan's annual emissions

Climate impact based on the additional $410B of market over the current projection.

Partner with Unblok

Support at every stage of scale-up

Early stage

Guide development

TEA/LCA tools to steer process development toward commercial economics.

Mid stage

Move faster

Plug-and-play, scalable equipment for faster bench-to-pilot transitions.

Scale-up

Build the plant

End-to-end platform strategy, equipment and commissioning support.

Capacity expansion

Hyperscale

A hyperscaling-ready platform for commodity biomanufacturing.

We work only in the B2B middle of the value chain. We don't develop proprietary strains, cell lines or consumer products, so we never compete with our partners.

Team

Built by a bioprocess operator and company builder

Zheng Huang, Ph.D.

Zheng Huang, Ph.D.

Founder & CEO
  • 20+ years of bioprocessing and industrial manufacturing experience
  • Former Ark Biotech CTO: built a market-validated bioprocess SaaS platform in 24 months and took a first-of-a-kind 1,000L bioreactor from idea to field operation in 18 months
  • Former Sanofi technical leader, supporting a multibillion-dollar U.S. manufacturing portfolio across 10 commercial products and 5 sites
  • Deep-tech entrepreneur with 6 issued patents and 5 provisionals in the past four years
Get in touch

Let's make bio-made products profitable

Whether you're developing a bio-based product, running a CDMO or investing in the bioeconomy, we'd like to hear from you.

zheng@unblokbio.com

Zheng Huang, Ph.D. · Founder & CEO · Unblok Bioprocess, Inc.